Successful treatment of human waldenström's macroglobulinemia with combination biological and chemotherapy agents

Ramzi M. Mohammad, Ayad Al-Katib, George Pettit, Lyle L. Sensenbrenner

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

The immunomodulating effects and antitumor activity of two biological agents, bryostatin 1 (Bryol) and α-interferon, were tested in vitro and in vivo either alone or prior to chemotherapy agents, against a Waldenström's macroglobulinemia tumor line (WSU-WM). Bryol caused a decrease in the expression of CD10, CD19, IgM, Leu10, and CD22 and a temporary growth inhibition as measured by cell cycle analysis. α-Interferon did not show any major effects. In vivo, severe combined immunodeficient mice were used to test the activity of the agents against WSUWM. Bryol (i.p.) was given either alone or sequentially with doxorubicin (i.v.), vincristine (i.v.), melphalan (i.v.), and α-Interferon (i.v.). Bryol given 24 h before vincristine or melphalan resulted in the highest tumor growth inhibition, tumor growth delay, and tumor cell kill. Two of five mice receiving Bryol/vincristine combination were free of tumors >200 days after treatment and were considered cured. In light of our findings, we recommend that Bryol be considered for clinical investigation in human B-cell tumors and might best be given combined with other chemotherapy agents used in the treatment of that disease. Whether Bryol is acting as a differentiating agent or as a direct anti-Waldenström's macroglobulinemia tumor agent, remains unclear.

Original languageEnglish (US)
Pages (from-to)165-168
Number of pages4
JournalCancer Research
Volume54
Issue number1
StatePublished - Jan 1 1994

Fingerprint

Waldenstrom Macroglobulinemia
Biological Factors
Combination Drug Therapy
Vincristine
Neoplasms
Interferons
Melphalan
Therapeutics
Growth
Drug Therapy
SCID Mice
Doxorubicin
Immunoglobulin M
Cell Cycle
B-Lymphocytes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Successful treatment of human waldenström's macroglobulinemia with combination biological and chemotherapy agents. / Mohammad, Ramzi M.; Al-Katib, Ayad; Pettit, George; Sensenbrenner, Lyle L.

In: Cancer Research, Vol. 54, No. 1, 01.01.1994, p. 165-168.

Research output: Contribution to journalArticle

Mohammad, Ramzi M. ; Al-Katib, Ayad ; Pettit, George ; Sensenbrenner, Lyle L. / Successful treatment of human waldenström's macroglobulinemia with combination biological and chemotherapy agents. In: Cancer Research. 1994 ; Vol. 54, No. 1. pp. 165-168.
@article{a80763561fb64f3b8d9ae66d2ddc2571,
title = "Successful treatment of human waldenstr{\"o}m's macroglobulinemia with combination biological and chemotherapy agents",
abstract = "The immunomodulating effects and antitumor activity of two biological agents, bryostatin 1 (Bryol) and α-interferon, were tested in vitro and in vivo either alone or prior to chemotherapy agents, against a Waldenstr{\"o}m's macroglobulinemia tumor line (WSU-WM). Bryol caused a decrease in the expression of CD10, CD19, IgM, Leu10, and CD22 and a temporary growth inhibition as measured by cell cycle analysis. α-Interferon did not show any major effects. In vivo, severe combined immunodeficient mice were used to test the activity of the agents against WSUWM. Bryol (i.p.) was given either alone or sequentially with doxorubicin (i.v.), vincristine (i.v.), melphalan (i.v.), and α-Interferon (i.v.). Bryol given 24 h before vincristine or melphalan resulted in the highest tumor growth inhibition, tumor growth delay, and tumor cell kill. Two of five mice receiving Bryol/vincristine combination were free of tumors >200 days after treatment and were considered cured. In light of our findings, we recommend that Bryol be considered for clinical investigation in human B-cell tumors and might best be given combined with other chemotherapy agents used in the treatment of that disease. Whether Bryol is acting as a differentiating agent or as a direct anti-Waldenstr{\"o}m's macroglobulinemia tumor agent, remains unclear.",
author = "Mohammad, {Ramzi M.} and Ayad Al-Katib and George Pettit and Sensenbrenner, {Lyle L.}",
year = "1994",
month = "1",
day = "1",
language = "English (US)",
volume = "54",
pages = "165--168",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Successful treatment of human waldenström's macroglobulinemia with combination biological and chemotherapy agents

AU - Mohammad, Ramzi M.

AU - Al-Katib, Ayad

AU - Pettit, George

AU - Sensenbrenner, Lyle L.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - The immunomodulating effects and antitumor activity of two biological agents, bryostatin 1 (Bryol) and α-interferon, were tested in vitro and in vivo either alone or prior to chemotherapy agents, against a Waldenström's macroglobulinemia tumor line (WSU-WM). Bryol caused a decrease in the expression of CD10, CD19, IgM, Leu10, and CD22 and a temporary growth inhibition as measured by cell cycle analysis. α-Interferon did not show any major effects. In vivo, severe combined immunodeficient mice were used to test the activity of the agents against WSUWM. Bryol (i.p.) was given either alone or sequentially with doxorubicin (i.v.), vincristine (i.v.), melphalan (i.v.), and α-Interferon (i.v.). Bryol given 24 h before vincristine or melphalan resulted in the highest tumor growth inhibition, tumor growth delay, and tumor cell kill. Two of five mice receiving Bryol/vincristine combination were free of tumors >200 days after treatment and were considered cured. In light of our findings, we recommend that Bryol be considered for clinical investigation in human B-cell tumors and might best be given combined with other chemotherapy agents used in the treatment of that disease. Whether Bryol is acting as a differentiating agent or as a direct anti-Waldenström's macroglobulinemia tumor agent, remains unclear.

AB - The immunomodulating effects and antitumor activity of two biological agents, bryostatin 1 (Bryol) and α-interferon, were tested in vitro and in vivo either alone or prior to chemotherapy agents, against a Waldenström's macroglobulinemia tumor line (WSU-WM). Bryol caused a decrease in the expression of CD10, CD19, IgM, Leu10, and CD22 and a temporary growth inhibition as measured by cell cycle analysis. α-Interferon did not show any major effects. In vivo, severe combined immunodeficient mice were used to test the activity of the agents against WSUWM. Bryol (i.p.) was given either alone or sequentially with doxorubicin (i.v.), vincristine (i.v.), melphalan (i.v.), and α-Interferon (i.v.). Bryol given 24 h before vincristine or melphalan resulted in the highest tumor growth inhibition, tumor growth delay, and tumor cell kill. Two of five mice receiving Bryol/vincristine combination were free of tumors >200 days after treatment and were considered cured. In light of our findings, we recommend that Bryol be considered for clinical investigation in human B-cell tumors and might best be given combined with other chemotherapy agents used in the treatment of that disease. Whether Bryol is acting as a differentiating agent or as a direct anti-Waldenström's macroglobulinemia tumor agent, remains unclear.

UR - http://www.scopus.com/inward/record.url?scp=0028089047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028089047&partnerID=8YFLogxK

M3 - Article

VL - 54

SP - 165

EP - 168

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 1

ER -